MRI contrast media developer Advanced Magnetics has signed two clinical trial agreements with the National Cancer Institute's Biomedical Imaging Program (BIP). In cooperation with Advanced Magnetics, BIP will sponsor clinical trials of the vendor's Combidex and Code 7228 MRI contrast agents in the detection of metastatic disease in lymph nodes, according to the Cambridge, MA-based company. Cytogen of Princeton, NJ, holds exclusive rights to the two agents for the detection of lymph node metastases and oncology applications.
By AuntMinnie.com staff writersOctober 1, 2002
Related Reading
Contrast agents herald new progress in MR lymphography, August 9, 2002
Advanced Magnetics revenues down in Q3, July 23, 2002
Advanced Magnetics shows Q2, six-month gains, April 19, 2002
Advanced Magnetics restates FY 2001 results, January 31, 2002
Advanced Magnetics turns Q4, 2001 profit, November 4, 2001
Copyright © 2002 AuntMinnie.com
